Key facts
- It has raised $16.7M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Jinlan Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Morebio
- ·The full record, as it builds
Funding rounds
No funding rounds for Morebio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Morebio
Operator of a biotechnology firm intended to advance the development and production of peptide-based therapeutics through genetic engineering and modern peptide technologies. The company offers a full-spectrum peptide drug R&D infrastructure, including GMP-compliant manufacturing platforms and proprietary expression systems, enabling pharmaceutical companies and research institutions to access high-quality peptide drugs and biologics with enhanced precision and scalability.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2008
- Employees
- 19
- Website
- more-bio.com/
- Ownership
- Privately Held (backing)
Morebio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Morebio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Morebio in its N-PORT filings yet. We sweep new filings monthly.